A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects

Transfusion

Volumn 55, Issue 6, 2015, Pages 1501-1511

  Yu, Xiaojie ^a,b   Menard, Melissa ^b,e   Seabright, Gemma ^c,d   Crispin, Max ^d   Lazarus, Alan H ^a,b,e  

^a CANADIAN BLOOD SERVICES   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c University of Bath   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; FC RECEPTOR; FC RECEPTOR IIB; GLYCAN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; RHESUS D ANTIBODY; ALLOANTIBODY; MONOCLONAL ANTIBODY; RHO(D) ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DEGLYCOSYLATION; ERYTHROCYTE; FEMALE; FUCOSYLATION; IMMUNE THROMBOCYTOPENIA; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; THROMBOCYTE; THROMBOCYTOPENIA; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DISEASE MODEL; GLYCOSYLATION; IMMUNOLOGY; METABOLISM; OUTBRED STRAIN; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

ANIMALS; ANIMALS, OUTBRED STRAINS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; GLYCOSYLATION; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; ISOANTIBODIES; MICE; MICE, INBRED C57BL; PROTEIN STRUCTURE, TERTIARY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 84931561591     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13032     Document Type: Article

References (56)

1. Lazarus AH, Crow AR,. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci 2003; 28: 249-55.
2. Brinc D, Lazarus AH,. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Hematology Am Soc Hematol Educ Program 2009; 185-91.
3. Blanchette V, Imbach P, Andrew M, et al., Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994; 344: 703-7.
4. Scaradavou A, Woo B, Woloski BM, et al., Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997; 89: 2689-700.
5. Kumpel BM,. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang 2007; 93: 99-111.
6. Lazarus AH,. Monoclonal versus polyclonal anti-D in the treatment of ITP. Expert Opin Biol Ther 2013; 13: 1353-6.
7. Neppert J, von Witzleben-Schurholz EM,. Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D: lack of efficiency due to absence of Fc gammaR-inhibiting activity? Transfusion 1997; 37: 444-5; author reply 445-6.
8. Sandilands GP, Atrah HI, Templeton G, et al., In vivo and in vitro blocking of human lymphocyte Fc gamma-receptors by intravenous gammaglobulin. J Clin Lab Immunol 1987; 23: 109-15.
9. Godeau B, Oksenhendler E, Brossard Y, et al., Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D. Transfusion 1996; 36: 328-30.
10. Robak T, Windyga J, Trelinski J, et al., Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood 2012; 120: 3670-6.
11. Lazarus AH, Freedman J, Semple JW,. Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action. Transfus Sci 1998; 19: 289-94.
12. Bussel JB, Graziano JN, Kimberly RP, et al., Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 1991; 77: 1884-93.
13. Boughton BJ,. Anti-D Ig for treatment of immune thrombocytopenic purpura. Blood 1991; 78: 2157-8.
14. Oksenhendler E, Bierling P, Brossard Y, et al., Anti-RH immunoglobulin therapy for human immunodeficiency virus-related immune thrombocytopenic purpura. Blood 1988; 71: 1499-502.
15. Cooper N, Heddle NM, Haas M, et al., Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol 2004; 124: 511-8.
16. Ambriz-Fernandez R, Martinez-Murillo C, Quintana-Gonzalez S, et al., Fc receptor blockade in patients with refractory chronic immune thrombocytopenic purpura with anti-D IgG. Arch Med Res 2002; 33: 536-40.
17. Crow AR, Song S, Semple JW, et al., IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001; 115: 679-86.
18. Schwab, I, Mihai, S, Seeling, M, et al., Broad requirement for terminal sialic acid residues and FcgammaRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo. Eur J Immunol 2014; 44: 1444-53.
19. Bazin R, Lemieux R, Tremblay T, et al., Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells. Br J Haematol 2004; 127: 90-6.
20. Song S, Crow AR, Freedman J, et al., Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 2003; 101: 3708-13.
21. Kina T, Ikuta K, Takayama E, et al., The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br J Haematol 2000; 109: 280-7.
22. Crow AR, Song S, Suppa SJ, et al., Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP? Blood 2011; 117: 971-4.
23. Song S, Crow AR, Siragam V, et al., Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 2005; 105: 1546-8.
24. Deng R, Balthasar JP,. Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. Blood 2007; 109: 2470-6.
25. Katsman Y, Foo AH, Leontyev D, et al., Improved mouse models for the study of treatment modalities for immune-mediated platelet destruction. Transfusion 2010; 50: 1285-94.
26. Aubin E, Lemieux R, Bazin R,. Absence of cytokine modulation following therapeutic infusion of intravenous immunoglobulin or anti-red blood cell antibodies in a mouse model of immune thrombocytopenic purpura. Br J Haematol 2007; 136: 837-43.
27. Chen X, Ghaffar H, Jen CC, et al., Antibody specific for the glycophorin A complex mediates intravenous immune globulin-resistant anemia in a murine model. Transfusion 2014; 54: 655-64.
28. Brain MC, Prevost JM, Pihl CE, et al., Glycophorin A-mediated haemolysis of normal human erythrocytes: evidence for antigen aggregation in the pathogenesis of immune haemolysis. Br J Haematol 2002; 118: 899-908.
29. Brain MC, Ruether B, Valentine K, et al., Life-threatening hemolytic anemia due to an autoanti-Pr cold agglutinin: evidence that glycophorin A antibodies may induce lipid bilayer exposure and cation permeability independent of agglutination. Transfusion 2010; 50: 292-301.
30. Dilillo DJ, Tan GS, Palese P, et al., Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med 2014; 20: 143-51.
31. Bournazos S, Klein F, Pietzsch J, et al., Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 2014; 158: 1243-53.
32. Goede V, Fischer K, Busch R, et al., Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-10.
33. Nimmerjahn F, Ravetch JV,. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34-47.
34. Jefferis R, Lund J, Pound JD,. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev 1998; 163: 59-76.
35. Arnold JN, Wormald MR, Sim RB, et al., The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25: 21-50.
36. Nimmerjahn F, Ravetch JV,. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005; 310: 1510-2.
37. Bowden TA, Baruah K, Coles CH, et al., Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis. J Am Chem Soc 2012; 134: 17554-63.
38. Yu X, Baruah K, Harvey DJ, et al., Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. J Am Chem Soc 2013; 135: 9723-32.
39. Ravetch JV, Bolland S,. IgG Fc receptors. Annu Rev Immunol 2001; 19: 275-90.
40. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al., Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98: 1095-9.
41. Nieswandt B, Echtenacher B, Wachs FP, et al., Acute systemic reaction and lung alterations induced by an antiplatelet integrin gpIIb/IIIa antibody in mice. Blood 1999; 94: 684-93.
42. Cannon, GJ, Swanson JA., The macrophage capacity for phagocytosis. J Cell Sci 1992; 101 (Pt 4): 907-13.
43. Kurlander RJ, Hall J,. Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 1986; 77: 2010-8.
44. Khodoun MV, Kucuk ZY, Strait RT, et al., Rapid desensitization of mice with anti-FcγRIIb/FcγRIII mAb safely prevents IgG-mediated anaphylaxis. J Allergy Clin Immunol 2013; 132: 1375-87.
45. Nimmerjahn F, Bruhns P, Horiuchi K, et al., FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005; 23: 41-51.
46. Nimmerjahn F, Ravetch JV,. Fcgamma receptors: old friends and new family members. Immunity 2006; 24: 19-28.
47. Ferrara C, Stuart F, Sondermann P, et al., The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006; 281: 5032-6.
48. Ferrara C, Grau S, Jäger C, et al., Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A 2011; 108: 12669-74.
49. Herbst R, Wang Y, Gallagher S, et al., B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 2010; 335: 213-22.
50. Jefferis R,. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 2005; 21: 11-6.
51. Holland M, Yagi H, Takahashi N, et al., Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. Biochim Biophys Acta 2006; 1760: 669-77.
52. Cooper N,. Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia. Hematol Oncol Clin North Am 2009; 23: 1317-27.
53. Lux A, Yu X, Scanlan CN, et al., Impact of immune complex size and glycosylation on IgG binding to human FcγRs. J Immunol 2013; 190: 4315-23.
54. Kanda Y, Yamada T, Mori K, et al., Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 2007; 17: 104-18.
55. Stockmann H, Adamczyk B, Hayes J, et al., Automated, high-throughput IgG-antibody glycoprofiling platform. Anal Chem 2013; 85: 8841-9.
56. Harvey DJ, Merry AH, Royle L, et al., Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics 2009; 9: 3796-801.